FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Vashington,	$D \subset$	205/10
vasiiiigioii,	D.C.	20349

STATEMENT	OF CHANGES	IN BENEFICIAL	OWNERSHIP

	OMB APPROVAL								
	OMB Number: 3235-028 Estimated average burden								
	hours per response	0.5							

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* Silver Brian M.				2. Issuer Name and Ticker or Trading Symbol TScan Therapeutics, Inc. [TCRX]					(Che	eck all applic Directo			on(s) to Issu 10% Ow Other (sp	wner		
(Last)	`	,	(Middle)		3. Date of Earliest Transaction (Month/Day/Year) 06/13/2023							below)				
C/O TSCAN THERAPEUTICS, INC.					4 If Amandanant Data of Original Filed (Marth/Day/March)					6 10	6 Individual or Joint/Croup Filing (Cheek Aralizable					
830 WIN	TER STRE	ŒT		"	4. If Amendment, Date of Original Filed (Month/Day/Year)						6. Individual or Joint/Group Filing (Check Applicable Line)					
(Stroot)											2	K Form fi	led by One I	Repor	ting Person	
(Street) WALTH	AM M	ΙA	02451									Form filed by More than One Reporting Person				ing
(City)	(S	tate)	(Zip)	F	Rule 10b5-1(c) Transaction Indication											
				[Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.							to				
	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned															
Date			2. Transactio Date Month/Day/	Execution Date,		Code (Instr. 5)		red (A) or ıstr. 3, 4 and	5. Amour Securitie Beneficia Owned F	s Form ally (D) or ollowing (I) (In		Direct of Endirect str. 4)	. Nature f Indirect seneficial ownership			
							Code	V Amoun	t (A)	or Price	Reported Transaction(s) (Instr. 3 and 4)			"	nstr. 4)	
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																
1. Title of Derivative Security (Instr. 3)	1. Title of 2. 3. Transaction Date Execution Date, Transaction Conversion (Month/Day/Year) if any Co		te, Trans Code	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year) (Month/Day/Year) 7. Title and of Securitie Underlying Derivative (Instr. 3 and		ies g Security	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s)	y	Ownership of Form: Be Direct (D) Ov	11. Nature of Indirect Beneficial Ownership (Instr. 4)			
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		(Instr. 4)			
Stock Option (Right to Buy)	\$2.49	06/13/2023		A		632,500		(1)	06/12/2033	Voting Common Stock	632,500	\$0.00	632,500		D	

Explanation of Responses:

1. 302,500 shares subject to this option shall vest and become exercisable with respect to 25% of the shares on the one-year anniversary of May 24, 2023, with the balance vesting thereafter in equal monthly installments over the next 36 months of continuous service to the Issuer. The remaining 330,000 shares subject to this option shall vest and become exercisable with respect to 25% of the shares on February 2, 2025, with the balance vesting thereafter in equal monthly installments over the next 36 months of continuous service to the Issuer, in each case subject to the Reporting Person's continued service at such time. This option was granted on May 24, 2023 subject to the approval of the Issuers' stockholders of an amendment to the TScan Therapeutics, Inc. 2021 Equity Incentive Plan, which was obtained on June 13, 2023.

Remarks:

/s/ Brian M. Silver

** Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.